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Summary
 
CD22 is a B cell–specific transmembrane protein known to function as a negative regulator of
B cell signaling. It has also been implicated in cell adhesion through recognition of 
 
a
 
2,6-linked
sialic acids on glycans of target cells. Previous studies showed that CD22-deficient mice had a
strongly reduced population of mature recirculating B cells in the bone marrow despite normal
B cell development. Using a soluble recombinant form of the receptor (CD22-Fc), we demon-
strate here that sialylated ligands for CD22 are expressed on sinusoidal endothelial cells of mu-
rine bone marrow but not on endothelial cells in other tissues examined. Injection of CD22-Fc
revealed that the CD22 ligands in the bone marrow were accessible to the circulation. Treat-
ment of mice with either CD22-Fc or affinity-purified anti-CD22 antibody led to an 
 
z
 
50%
reduction in mature recirculating B cells in the bone marrow without affecting numbers in the
spleen. Finally, consistent with the notion that CD22 is a homing receptor, we show that com-
pared with wild-type mice, CD22-deficient animals have a lower number of immunoglobulin
M–secreting plasma cells in the bone marrow.
Key words: lymphocyte homing • B cells • sialic acid binding • siglec • CD22
 
C
 
D22 is a B lymphocyte–restricted member of the Ig
superfamily with seven Ig-like extracellular domains.
It appears on the cell surface at the pre-B cell stage and is
lost as B cells differentiate into plasma cells. CD22 is one of
a group of transmembrane molecules on the B cell surface
which modulate the quality and strength of the B cell anti-
gen receptor (BCR) signal (for a review, see reference 1).
After BCR engagement, CD22 is tyrosine phosphorylated
on its cytoplasmic tail, which results in recruitment and ac-
tivation of the tyrosine phosphatase SHP-1 (1, 2). We and
others generated CD22-deficient mice and found that their
B cells gave an increased and prolonged Ca
 
2
 
1
 
 signal after
BCR stimulation (3–6). The hyperactivation resulted in an
increased rate of apoptosis of CD22-deficient B cells in
vitro and a reduced life span of B cells from CD22-defi-
cient mice in vivo. However, the deficiency in CD22 did
not greatly perturb B cell development or induction of im-
mune responses in the mutant mice (3).
The extracellular region of CD22 shares sequence simi-
larity with the siglec subgroup of Ig superfamily proteins
which recognize sialylated glycoconjugates rather than
protein determinants as their dominant ligands (7). When
CD22 cDNAs were expressed in Chinese hamster ovary
(CHO) or COS cells, the recombinant protein mediated
sialic acid (Sia)-dependent binding of various cell types, in-
cluding lymphocytes, erythrocytes, and activated endothe-
lial cells (8, 9). Specificity studies showed that CD22 has an
absolute requirement for 
 
a
 
2,6-linked Sia, preferably on
multiantennary oligosaccharide chains (8, 10). This Sia link-
age depends on the expression of 
 
a
 
2,6 sialyltransferases
such as ST6GalI, which transfers Sia to the nonreducing
termini of 
 
N
 
-glycans (11).
The adhesive function of CD22 is complicated by the
fact that the lectin binding site can be masked by 
 
cis
 
-inter-
actions with 
 
a
 
2,6-linked Sia on the same plasma membrane
(9, 12). Unlike CHO or COS cells, which do not normally
express ST6GalI, B cells regulate the expression of this en-
zyme and usually display high levels of 
 
a
 
2,6-linked Sia at
the cell surface (9). This raises the important question of
whether CD22 expressed naturally on B cells is able to me-
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diate cell–cell interactions. In this regard, it was shown re-
cently that the Sia binding activity of CD22 on resting hu-
man peripheral blood B cells was undetectable, but could
be observed on a subset of cells after cellular activation (13).
In adult mice, B cells develop in the bone marrow up
to the stage when they express surface IgM. As IgM
 
high
 
(IgM
 
hi
 
) transitional cells (14), they leave the bone marrow
and migrate to peripheral lymphoid tissues where they are
thought to mature to long-lived IgM
 
low
 
IgD
 
high
 
 (IgM
 
lo
 
IgD
 
hi
 
)
cells (15, 16). These IgD
 
hi
 
 B cells recirculate through the
blood and migrate back to tissues, among them the bone
marrow. Interestingly, we and other groups noted that the
population of recirculating B cells was specifically reduced
in the bone marrow of CD22-deficient mice, despite a
normal number of these cells in the lymph nodes, spleen,
and blood (3–6). Furthermore, by adoptive transfer studies
we demonstrated that there was a twofold higher repopula-
tion of the bone marrow of RAG2
 
2
 
/
 
2
 
 mice with injected
wild-type B cells than with CD22-deficient B cells. These
findings suggested that CD22 could be directly or indi-
rectly involved in homing of this subset of B cells to the
bone marrow (3). Here, we present evidence for a direct
CD22-dependent homing process of recirculating B cells
to the bone marrow.
 
Materials and Methods
 
All reagents were purchased from Sigma unless stated otherwise.
 
Animals.
 
C57BL/6, BALB/c, and CD22-deficient mice on a
C57BL/6 background were obtained from our breeding facility.
For immunocytochemical staining experiments, female BALB/c
mice were purchased from Charles River. Most experiments
were done with mice at 6–8 wk of age.
 
Preparation of Fc Protein.
 
Fc proteins used in this study were
composed of the first three NH
 
2
 
-terminal extracellular Ig-like
domains of siglecs fused to the Fc portion of human IgG1. The
cDNAs encoding CD22-Fc, the mutant CD22(R130E)-Fc, sialo-
adhesin (Sn)-Fc, and myelin-associated glycoprotein (MAG)-Fc
have been described previously (8, 17). CD22-Fc, MAG-Fc, and
Sn-Fc proteins were produced in CHO cells stably transfected
using a glutamine synthetase expression system (18) and purified
as described (8). In the comparative staining experiment with
CD22(R130E)-Fc and CD22-Fc, concentrated tissue culture su-
pernatants were used that had been predetermined by ELISA to
contain immunoreactive Fc protein at 0.15 mg/ml (17).
 
Immunocytochemistry.
 
Femoral bone marrow plugs and other
tissues were fixed in 4% paraformaldehyde in PBS for 1 h at room
temperature, transferred sequentially for 30 min each into 5, 15,
and 30% sucrose in PBS, and then frozen in OCT (Miles, Inc.).
7-
 
m
 
m cryostat sections were treated with methanol plus 0.3%
H
 
2
 
O
 
2
 
 and then incubated for 1 h with Fc proteins at 10 
 
m
 
g/ml,
followed sequentially by biotinylated anti–human Fc, ABC
reagent, and diaminobenzidine (Vector Laboratories). Staining
with biotin–
 
Sambucus nigra
 
 agglutinin (SNA; Vector Laboratories)
at 1 
 
m
 
g/ml was performed similarly. Before staining in some experi-
ments, sections were pretreated for 3 h at 37
 
8
 
C with 0.2 U/ml
 
Arthrobacter ureafaciens
 
 sialidase (ICN) in 0.1 M sodium acetate
buffer, pH 5.0, in the presence or absence of 20 mM 2,3-dehydro-
2-deoxy 
 
N
 
-acetyl neuraminic acid (2,3-DDN; Boehringer Mann-
heim).
 
Electron Microscopy.
 
Bone marrow fragments were fixed for 1 h
in 2% paraformaldehyde in 0.1 M phosphate buffer, washed exten-
sively, and incubated for 12 h at 4
 
8
 
C with CD22-Fc or MAG-Fc
(20 
 
m
 
g/ml) followed by goat anti–human Ig-peroxidase. Diami-
nobenzidine was used for visualization of reaction sites. The sam-
ples were postfixed in osmium tetroxide in 0.1 M phosphate
buffer, dehydrated, and embedded in Spurr’s epoxy resin. Thin
sections were cut and examined in a Jeol 1200EX electron micro-
scope.
 
In Vivo Treatments.
 
(a) BALB/c mice were injected intrave-
nously with 0.15 mg of CD22-Fc or 0.15 mg MAG-Fc as a con-
trol, and killed 2 h later. Bone marrow plugs and spleens were
processed and stained as described above, except that no primary
antibody was used. (b) BALB/c or C57BL/6 mice (four mice per
group) were injected once intravenously with 0.5 mg CD22-Fc
or 0.5 mg Sn-Fc as a control, killed 24 h later, and cells were an-
alyzed by flow cytometry. Samples of blood were taken after 12,
24, and 72 h, and the concentration of CD22-Fc was determined
by an ELISA, as described (17). (c) Every 3 d over a period of 2 wk,
4-wk-old C57BL/6 mice were injected intraperitoneally with
0.5 mg of affinity-purified polyclonal rabbit anti-CD22 or with
control rabbit IgG that did not bind to the CD22-Fc affinity col-
umn during purification (8). The mice were then killed, and the
cellular composition in spleens and bone marrow of individual
mice was analyzed by flow cytometry.
 
Flow Cytometry.
 
Flow cytometry was performed as described
(3) using three-color staining of lymphocytes. The following an-
tibodies and reagents were used: FITC- and biotin-rat anti-IgD
(11-26C; our hybridoma collection), FITC- and PE-rat anti-
B220 (RA3-6B2; PharMingen), PE-goat anti–mouse F(ab
 
9
 
)
 
2
 
 IgM
(Medac), PE-mouse anti-CD22 (Cy34.1; PharMingen), and
streptavidin-Red 670 (Life Technologies).
 
Elispot Assay.
 
An enzyme-linked immunospot (Elispot) assay
was carried out as described (19). Bone marrow and spleen cells
from three CD22-deficient mice and three age-matched control
mice were prepared and pooled for each group, and the Elispot
was performed in triplicate. Plates were coated with goat anti–
mouse IgM or with goat anti–mouse IgG (Southern Biotechnol-
ogy). After overnight incubation of cells plated at varying con-
centrations, they were washed off, and the spots were revealed
with alkaline phosphatase–conjugated goat anti–mouse IgM or
IgG antibodies (Southern Biotechnology).
 
Results
 
Identification of CD22 Ligands on Bone Marrow Sinusoidal
Endothelium.
 
If the lectin activity of CD22 is directly in-
volved in bone marrow homing of recirculating B cells, we
reasoned that ligands for CD22 should be expressed within
this tissue. This was investigated by staining sections of
bone marrow with CD22-Fc, a soluble Fc chimera con-
taining the NH
 
2
 
-terminal three Ig-like domains of mouse
CD22. In the bone marrow, CD22-Fc stained tubular
structures corresponding to the network of branched sinu-
soids (Fig. 1, A and B). A few rare scattered cells in the he-
matopoietic spaces were also stained. In contrast, no vascular
structures were stained in other organs examined, including
spleen (Fig. 1 C), lymph node, heart, and liver (not shown).
However, in spleen (Fig. 1 C) and lymph node (not
shown), CD22-Fc gave clear staining of B lymphocytes in
follicles, together with scattered T cells, as shown previ- 
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ously (20). No staining of any tissues was observed with the
related proteins, MAG-Fc or Sn-Fc (not shown).
Specific staining of endothelial cells by CD22-Fc was con-
firmed by immunoelectron microscopy (Fig. 1, D and E).
The label was predominantly located along the luminal sur-
face of the sinusoidal endothelial cell that is normally ex-
posed to blood elements, with reduced labeling of the basal
surface (Fig. 1 D). In contrast, endothelial cells lining arte-
rioles and venules were unstained (not shown), as were the
great majority of hematopoietic cells.
 
CD22-Fc Binds Sialylated Ligands on Bone Marrow Sinusoidal
Endothelium.
 
Two lines of evidence indicated that the bind-
ing of CD22-Fc to bone marrow endothelium was Sia depen-
dent. First, no staining was observed with CD22(R130E)-Fc,
which carries an inactivating mutation within the Sia bind-
ing site (17; Fig. 1 F). Second, treatment of bone marrow
and spleen sections with 
 
A
 
.
 
 ureafaciens
 
 sialidase was found to
abolish binding of CD22-Fc, and this could be reversed by
addition of the sialidase inhibitor, 2,3-DDN (not shown).
We next compared CD22-Fc staining with that of SNA,
a plant lectin with a well-defined specificity for oligosac-
charides carrying 
 
a
 
2,6-linked Sia (21). Although the spleen
staining was comparable with both reagents (not shown),
the bone marrow showed striking differences, in particular
the apparent lack of staining of sinusoidal endothelium by
SNA (Fig. 1 G). However, SNA labeled a major subset of
cells in the hematopoietic spaces, most of which were unla-
beled by CD22-Fc. These results suggest that bone marrow
ligands recognized by CD22-Fc and SNA are distinct.
 
Inhibition of B Lymphocyte Homing to Bone Marrow In Vivo.
 
It was important to determine if CD22 is able to interact
with the sialylated bone marrow ligands in vivo
 
,
 
 since
plasma is rich in 
 
a
 
2,6-sialoglycoproteins which could com-
pete for binding. As shown in Fig. 1 H, intravenous injec-
tion of CD22-Fc resulted in a staining pattern in bone mar-
row similar to that observed after in vitro staining (Fig. 1
A), whereas injection of MAG-Fc did not result in detect-
able labeling (Fig. 1 I). The half-life of CD22-Fc in the cir-
culation was found to be 
 
z
 
56 h (data not shown).
To determine if circulating CD22-Fc could interfere
with localization of mature B cells to the bone marrow by
masking CD22 ligands, mice were given a single injection
of CD22-Fc, and B cell numbers were assayed after 24 h.
Compared with either Sn-Fc or PBS (not shown) used as
negative controls, injection of CD22-Fc led to a 50% re-
duction in the population of bone marrow IgD
 
1
 
 B cells
(Fig. 2 A, a and b), whereas immature (IgM
 
lo
 
IgD
 
2
 
) and
transitional (IgM
 
hi
 
IgD
 
lo
 
) B cells were unaffected (Fig. 2 A,
Figure 1. CD22-Fc binds spe-
cifically to bone marrow sinusoidal
endothelium in vitro and in vivo.
(A) Section of bone marrow re-
acted with CD22-Fc showing
widespread positive labeling of si-
nusoidal structures (arrows). (B)
Detail showing specific labeling of
the sinusoids. (C) Section of spleen
stained with CD22-Fc showing
positive labeling of the B cell folli-
cles. (D) Immunoelectron micros-
copy with CD22-Fc showing re-
action product on the luminal
surface (large arrow) of the endo-
thelial cell (En) with reduced
staining along the basal surface (ar-
rowheads) and no labeling of the
pericapillary cell process (small ar-
row). (E) Immunoelectron mi-
croscopy control showing the ab-
sence of endothelial cell (En)
staining with MAG-Fc. L, lym-
phocyte in lumen of sinus (S); Er,
erythroblast. (F) Section of bone
marrow stained with the mutant
protein, CD22(R130E)-Fc, show-
ing the absence of labeling. (G)
Section of bone marrow stained
with SNA showing the absence of
sinusoidal staining (arrows) but the
presence of many labeled hemato-
poietic cells. (H and I) Sections of
bone marrow from mice injected
with either CD22-Fc (H) or
MAG-Fc (I) showing specific la-
beling of the sinusoids in the
CD22-Fc–treated mouse only.
Bars, 500 mm (A, C, F–I); 222 mm
(B); and 0.5 mm (D and E). 
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c and d). There was no effect on B cell numbers in the
spleen (Fig. 2 A, e and f).
In an attempt to block the Sia binding site of CD22 in
vivo, 4-wk-old mice were injected with polyclonal rabbit
anti-CD22 IgG over a 2-wk period during which long-
lived B cells populate the marrow. Antibody treatment re-
sulted in a selective reduction in the numbers of recirculat-
ing IgD
 
1
 
 cells in the bone marrow, at 
 
z
 
50% of the cell
numbers present in control mice injected with nonspecific
rabbit IgG (Fig. 2 B, g and h). This reduction was not found
 
in the spleen (Fig. 2 B, i and j), and there was no effect on
numbers of immature or transitional B cells (not shown).
Unexpectedly, however, the treatment with anti-CD22 led
to a downmodulation of the molecule from the surface (Fig.
2 B, k and l), presumably due to internalization, and this
may have contributed to the reduction of mature B cells in
the bone marrow.
 
Bone Marrow of CD22-deficient Mice Is Depleted in Plasma
Cells.
 
The bone marrow is known to be a major site of Ig
secretion by plasma cells (22). To address the question of
whether the lack of recirculating B cells in the bone mar-
row of CD22-deficient mice would also affect plasma cells,
we determined their number in the bone marrow and
spleen of CD22-deficient and control mice. In the bone
marrow of CD22-deficient mice, there was a significant re-
duction of IgM-secreting plasma cells, whereas these cells
were increased in the spleen compared with wild-type
mice (Fig. 3). In this experiment, the number of IgG-
secreting plasma cells was also reduced in the bone marrow.
In two other experiments, the reduction of IgG-secreting
plasma cells in the bone marrow of CD22-deficient mice
was less pronounced, whereas IgM plasma cells were con-
sistently reduced (not shown).
 
Discussion
 
Here we present evidence that CD22 is a specific recep-
tor involved in the homing of long-lived recirculating B
cells to the bone marrow. Our demonstration that CD22
ligands are constitutively expressed on endothelial cells in
the bone marrow, but not in other organs, raises the attrac-
tive possibility that CD22 can function as a classical homing
receptor for the bone marrow by targeting cells to the ap-
propriate microenvironment. It has been reported that
IgD
 
1
 
 recirculating cells are found in the extravascular space,
mainly in perisinusoidal locations (15). The interaction with
CD22 ligands on endothelial cells could be an important
first step before transmigration of B cells into the bone
marrow parenchyma. Another possibility is that CD22
serves as a retention signal, preventing the reexit of B cells
from the bone marrow.
The reason for the incomplete block in B cell homing
after the in vivo treatments could be related to the rela-
Figure 2. CD22-Fc injection or treatment with anti-CD22 IgG re-
duces the number of recirculating IgD1 B cells in the bone marrow. (A)
C57BL/6 mice were injected once intravenously with either CD22-Fc or
Sn-Fc as a control. Bone marrow (BM; a–d) and spleen (Spl) cells (e and
f) were analyzed by flow cytometry 24 h later. Percentages of cells in
boxes are given. In the bone marrow, there was a specific reduction in
IgD1 cells (treatment: Sn-Fc, 11.1 6 2.8%; CD22-Fc, 5.6 6 3.8% IgDhi
cells, P , 0.05; n 5 4), but not in immature (IgMloIgD2) or transitional
(IgMhiIgDlo) B cells. There was no effect on B cells in the spleen (treat-
ment: Sn-Fc, 49.1 6 4.1%; CD22-Fc, 49.9 6 5.4% B2201IgD1 cells).
(B) BALB/c mice were given three intraperitoneal injections of rabbit
anti-CD22 IgG or control rabbit IgG over a period of 2 wk. Bone mar-
row (BM; g and h) and spleen (Spl) cells (i–l) were then analyzed by flow
cytometry. Percentages of cells in boxes are given. In the bone marrow,
there was a specific reduction in IgD1 cells (control IgG, 6.5 6 2.4%;
anti-CD22, 2.9 6 0.4% IgDhi cells, P , 0.05; n 5 4), but not in imma-
ture or transitional B cells (not shown). There was no effect on IgD1
B cells in the spleen (control IgG, 68.8 6 1.6%; anti-CD22, 66.2 6 2.4%
B2201IgD1 cells). The downmodulation of CD22 shown in panel l was
not due to the injected rabbit anti-CD22 masking the epitope, as tested
by staining with anti–rabbit IgG-FITC (not shown). One out of two ex-
periments with identical results is shown for A and B.
Figure 3. CD22-deficient mice
have a reduced number of plasma
cells in the bone marrow and an
enhanced number in the spleen.
The number of IgM- and IgG-
secreting plasma cells in bone
marrow (BM) and spleen (Spl) of
wild-type (black bars) and CD22-
deficient mice (hatched bars) was
determined by an Elispot assay.
All differences shown are signifi-
cant with P , 0.01, except for
bone marrow IgG at P  ,  0.05
(Student’s t test, n 5 3). The mean level of IgM was two times higher in
the serum of CD22-deficient mice, whereas there was no difference in IgG
levels between CD22-deficient and wild-type mice. One typical experi-
ment out of three performed is shown. 
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tively low affinity of the carbohydrate binding region of
CD22 (10). Alternatively, CD22-independent homing path-
ways may exist. Although most of the long-lived IgD
 
1
 
 cells
are thought to result from a maturation process in the pe-
ripheral lymphoid tissue (15, 16), it is possible that some of
these cells are produced locally in the bone marrow. In
support of this, CD22-deficient mice show an age-depen-
dent accumulation of IgD
 
1
 
 cells in the bone marrow (3;
our unpublished observations).
Expression of CD22 ligands is regulated by 
 
a
 
2,6-sialyl-
transferases, especially ST6GalI (10). Recently, a mouse
line deficient in ST6GalI was reported which had a normal
composition of B cells in the bone marrow, including ma-
ture recirculating B cells (23). If ST6GalI is the enzyme re-
sponsible for creation of the CD22 ligands implicated in B
cell homing, we would have expected a reduction of ma-
ture B cells in the bone marrow. The discrepancy could be
due to expression of an alternative 
 
a
 
2,6-sialyltransferase in
bone marrow endothelial cells or the use of compensatory
homing mechanisms in ST6GalI-deficient mice.
One obvious question is how CD22 on B cells is able to
bind ligands on other cells when its lectin binding site is
largely masked (13). Interestingly, we have recently found
that a significant subset of IgD
 
1
 
 B cells in murine bone
marrow is able to bind CD22 ligands, whereas only a mi-
nor subset of these cells binds in the spleen or lymph nodes
(Floyd, H., L. Nitschke, and P.R. Crocker, unpublished
observations). One interpretation of this observation is that
“lectin-competent” IgD
 
1
 
 B cells become selectively en-
riched in the bone marrow due to interactions with CD22
ligands expressed on bone marrow endothelial cells.
In both mice and humans, most of the IgD
 
1
 
 recirculat-
ing B cells carry rearranged Ig genes with only a small
number of somatic mutations (24). However, there is also
evidence that the pool of IgD
 
1 B cells in the human bone
marrow contains memory B cells with a large number of
somatic mutations (25). Isotype-switched plasma cells are
thought to be derived from precursors that encounter anti-
gen in germinal centers and then migrate to the bone mar-
row, which is a major site of Ig production. However, in
the case of IgM-secreting plasma cells, the locus of final
maturation is not well defined (22). It is possible that the
bone marrow is a site for the final maturation of these cells
from the pool of IgD1 recirculating B cells. This would be
consistent with our finding that CD22-deficient mice have
a reduced number of IgM-secreting plasma cells in this tis-
sue. An alternative explanation is that freshly activated,
IgM-secreting B cells are dependent on CD22 for homing
to the bone marrow.
Finally, an important question that remains is how the
adhesive activity of CD22 is coupled to its signaling func-
tion. Binding of the lectin domain to ligands in the bone
marrow microenvironment would be expected to influ-
ence the B cell signaling threshold and thereby determine
the fate of the B cell. The issue of how the signaling func-
tion is coupled to the lectin function of CD22 will be ad-
dressed in future experiments.
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